You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

TRETINOIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tretinoin patents expire, and what generic alternatives are available?

Tretinoin is a drug marketed by Barr Labs Inc, Endo Operations, Glenmark Pharms Ltd, Alembic, Allergan, Padagis Us, Taro, Zo Skin Health, Zydus Lifesciences, Mylan, Norvium Bioscience, Teva Pharms, Wockhardt, and Encube. and is included in twenty-two NDAs.

The generic ingredient in TRETINOIN is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tretinoin

A generic version of TRETINOIN was approved as tretinoin by PADAGIS US on December 24th, 1998.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRETINOIN?
  • What are the global sales for TRETINOIN?
  • What is Average Wholesale Price for TRETINOIN?
Drug patent expirations by year for TRETINOIN
Drug Prices for TRETINOIN

See drug prices for TRETINOIN

Drug Sales Revenue Trends for TRETINOIN

See drug sales revenues for TRETINOIN

Recent Clinical Trials for TRETINOIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas Southwestern Medical CenterPhase 2
Genentech, Inc.Phase 2
Indonesia UniversityN/A

See all TRETINOIN clinical trials

Pharmacology for TRETINOIN
Drug ClassRetinoid
Medical Subject Heading (MeSH) Categories for TRETINOIN
Paragraph IV (Patent) Challenges for TRETINOIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RETIN-A-MICRO Gel tretinoin 0.04% 020475 1 2010-12-20
RETIN-A-MICRO Gel tretinoin 0.1% 020475 1 2010-07-08

US Patents and Regulatory Information for TRETINOIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Barr Labs Inc TRETINOIN tretinoin CAPSULE;ORAL 077684-001 Jun 22, 2007 AB RX No Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Padagis Us TRETINOIN tretinoin GEL;TOPICAL 075589-001 Jun 11, 2002 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Padagis Us TRETINOIN tretinoin CREAM;TOPICAL 075264-001 Dec 24, 1998 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Alembic TRETINOIN tretinoin CREAM;TOPICAL 217804-001 Apr 29, 2024 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

TRETINOIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory of Tretinoin

Introduction to Tretinoin

Tretinoin, a derivative of vitamin A, is a topical medication primarily used to treat acne, signs of aging such as wrinkles and fine lines, and other dermatological conditions. Its mechanism involves increasing skin cell turnover, unclogging pores, and reducing inflammation.

Market Size and Forecast

The tretinoin market is poised for significant growth. As of 2024, the market size was valued at USD 2.5 billion and is projected to reach USD 7.5 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 10.1% during the forecast period of 2024-2031[1][3][4].

Drivers of Market Growth

Several factors are driving the growth of the tretinoin market:

Increasing Prevalence of Acne and Aging Skin

The rising prevalence of acne and the growing demand for anti-aging treatments are key drivers. Tretinoin's effectiveness in treating these conditions makes it a preferred choice among both dermatologists and consumers[3].

Advances in Formulations

Innovations in tretinoin formulations, including more stable and less irritating versions, have expanded its indications to include hyperpigmentation and other skin issues. This has further boosted market demand[3].

Patient Preference for Topical Treatments

Patients often prefer topical treatments for dermatological problems, and tretinoin's availability in various topical formulations caters to this preference, driving market demand[1].

Recommendations from Dermatologists

Dermatologists frequently recommend tretinoin for various skin issues, increasing consumer awareness and demand for products containing this ingredient[1].

Distribution Channels

Tretinoin products are available through several distribution channels:

Pharmacies and Drugstores

Over-the-counter tretinoin products are commonly found in pharmacies and drugstores[1].

Prescription Dispensing

Stronger formulations, particularly those for specific dermatological conditions, are dispensed through prescription by healthcare professionals[1].

Online Retail

The growing trend of online retail has made tretinoin-containing products accessible through e-commerce platforms, further expanding market reach[1].

Geographical Analysis

The global tretinoin market is segmented into several key regions:

North America

North America, particularly the United States and Canada, is a significant market due to the high prevalence of acne vulgaris and the early adoption of tretinoin products[4].

Europe

Europe is another major market, with countries like the U.K., Italy, Germany, and France showing strong demand for tretinoin[3][4].

Asia-Pacific

The Asia-Pacific region, especially Japan, is expected to provide substantial market opportunities due to the presence of companies like Chugai, which has released tretinoin products for various indications[4].

Middle East and Africa

The Middle East and Africa also show potential for growth, driven by increasing awareness and demand for skincare products[1][3].

Latin America

Latin America is another region with growing market dynamics, driven by expanding skincare and dermatological treatment markets[1][3].

Key Players and Market Competition

The tretinoin market is competitive, with several key players:

Major Pharmaceutical Companies

Companies such as Johnson & Johnson, Mylan N.V., Galderma S.A., Valeant Pharmaceuticals, and Teva Pharmaceutical Industries Ltd. are prominent in the market[2].

Research and Development

Companies like Sol-Gel Technologies are focused on developing and commercializing topical drug products, including those containing tretinoin, which contributes to market innovation and growth[5].

Financial Performance and Projections

The financial trajectory of the tretinoin market is robust:

Revenue Growth

The market is expected to see significant revenue growth, driven by the increasing demand for tretinoin products across various regions and distribution channels[1][3][4].

Research and Development Investments

Companies are investing heavily in research and development to improve formulations and expand indications for tretinoin, which is expected to further drive market growth[2][5].

Market Challenges and Opportunities

While the market faces challenges such as regulatory hurdles and competition, opportunities in emerging markets and the growing awareness of skincare provide a positive outlook for future growth[2][3].

"Market growth is driven by the increasing prevalence of acne, rising demand for anti-aging treatments, and the growing awareness of skincare. Advances in formulations, including more stable and less irritating versions, as well as expanding indications for its use, further contribute to the market's expansion."[3]

Key Takeaways

  • The tretinoin market is projected to grow significantly, reaching USD 7.5 billion by 2031.
  • Key drivers include the increasing prevalence of acne, demand for anti-aging treatments, and patient preference for topical treatments.
  • The market is segmented by distribution channels, including pharmacies, prescription dispensing, and online retail.
  • North America and Europe are major markets, with Asia-Pacific and other regions showing potential for growth.
  • Major pharmaceutical companies and ongoing research and development are crucial for market competition and innovation.

FAQs

What is the projected market size of tretinoin by 2031?

The tretinoin market is projected to reach USD 7.5 billion by 2031[1].

What are the primary drivers of the tretinoin market growth?

The primary drivers include the increasing prevalence of acne, rising demand for anti-aging treatments, and the growing awareness of skincare[3].

Which regions are the largest markets for tretinoin?

North America and Europe are currently the largest markets, with significant growth expected in the Asia-Pacific region as well[4].

What are the common distribution channels for tretinoin products?

Tretinoin products are available through pharmacies, prescription dispensing, and online retail[1].

Who are the key players in the tretinoin market?

Key players include Johnson & Johnson, Mylan N.V., Galderma S.A., Valeant Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.[2].

What role does research and development play in the tretinoin market?

Research and development are crucial for improving formulations, expanding indications, and driving market innovation and growth[2][5].

Sources

  1. Verified Market Research - Tretinoin Market Size, Share, Scope, Trends And Forecast
  2. Market Research Intellect - Tretinoin Drugs Industry Market Size, Scope and Forecast Report
  3. OpenPR - Tretinoin Market 2024 Trends Evaluation, Geographical Analysis, Challenges, and Investment Opportunities till 2031
  4. Fortune Business Insights - Tretinoin Market Size, Industry Share | Forecast 2032
  5. BioSpace - Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.